OPKO Health (NYSE: OPK) may have posted a net loss of $244 million on a trailing 12-month basis, but it had the wherewithal to buy Bio-Reference Laboratories (NASDAQ: BRLI), one of the largest full-service diagnostic laboratories in the world. Bio-Reference provides clinical testing services to physician offices, clinics, hospitals, long-term care facilities and employers in more than 50 countries. OPKO plans to leverage the company’s the national marketing, sales and distribution resources to boost sales of its 4Kscore test, a blood test that evaluates a patient’s risk for aggressive prostate cancer. Under terms of the deal, BRLI stockholders will receive 2.75 shares of OPKO common stock for each share of BRLI common stock. Based on a closing price of $19.12 per share of OPKO stock on June 3, 2015, the transaction is valued at approximately $1.47 billion.
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
